SPRY4-IT1 and breast cancer

Abstract

Abstract:

Long non-coding RNA （lncRNA） is an RNA molecule that does not code to express proteins， and plays an important role in the occurrence and development of a variety of tumors. As an lncRNA， SPRY4-IT1 is highly expressed in breast cancer tissues， and can be used as an upstream and downstream regulator of breast cancer， promoting the progression of breast cancer， and is closely related to breast cancer stage and prognosis. In-depth study of the molecular mechanism associated with SPRY4-IT1 and breast cancer can provide new ideas for discovering biomarkers for early diagnosis of breast cancer， assessing disease prognosis and finding targeting sites.

Key words:RNA， long noncoding,Breast neoplasms,SPRY4-IT1

Yan Xuemin, Wu Xiaoyong, Zhang Jiayi, Wen Jinxu, Wang Yuexin. SPRY4-IT1 and breast cancer[J]. Journal of International Oncology, 2023, 50(10): 627-630.

References32

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3): 209-249. DOI:10.3322/caac.21660.
[2]	Arnold M, Morgan E, Rumgay H, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040[J].Breast,2022,66: 15-23. DOI:10.1016/j.breast.2022.08.010. pmid:36084384
[3]	朱军, 黄美金, 李媛, 等. HER2低表达乳腺癌的靶向治疗研究进展[J].国际肿瘤学杂志,2023,50(4): 236-240. DOI:10.3760/cma.j.cn371439-20221230-00046.
[4]	Lee J. Current treatment landscape for early triple-negative breast cancer (TNBC)[J].J Clin Med,2023,12(4): 1524. DOI:10.3390/jcm12041524.
[5]	Ren Z, Xue Y, Liu L, et al. Tissue factor overexpression in triple-negative breast cancer promotes immune evasion by impeding T-cell infiltration and effector function[J].Cancer Lett,2023,565: 216221. DOI:10.1016/j.canlet.2023.216221.
[6]	Qian X, Zhao J, Yeung PY, et al. Revealing lncRNA structures and interactions by sequencing-based approaches[J].Trends Biochem Sci,2019,44(1): 33-52. DOI:10.1016/j.tibs.2018.09.012. pmid:30459069
[7]	Bridges MC, Daulagala AC, Kourtidis A. LNCcation: lncRNA loca-lization and function[J].J Cell Biol,2021,220(2): e202009045. DOI:10.1083/jcb.202009045.
[8]	Abd-Elmawla MA, Hassan M, Elsabagh YA, et al. Deregulation of long noncoding RNAs ANCR, TINCR, HOTTIP and SPRY4-IT1 in plasma of systemic sclerosis patients: SPRY4-IT1 as a novel biomarker of scleroderma and its subtypes[J].Cytokine,2020,133: 155124. DOI:10.1016/j.cyto.2020.155124.
[9]	Fan MJ, Zou YH, He PJ, et al. Long non-coding RNA SPRY4-IT1 promotes epithelial-mesenchymal transition of cervical cancer by regulating the miR-101-3p/ZEB1 axis[J].Biosci Rep,2019,39(6): BSR20181339. DOI:10.1042/BSR20181339.
[10]	Cao S, Lin L, Xia X, et al. lncRNA SPRY4-IT1 regulates cell proliferation and migration by sponging miR-101-3p and regulating AMPK expression in gastric cancer[J].Mol Ther Nucleic Acids,2019,17: 455-464. DOI:10.1016/j.omtn.2019.04.030.
[11]	Ghafouri-Fard S, Khoshbakht T, Taheri M, et al. A review on the role of SPRY4-IT1 in the carcinogenesis[J].Front Oncol,2021,11: 779483. DOI:10.3389/fonc.2021.779483.
[12]	Safa A, Gholipour M, Dinger ME, et al. The critical roles of lncRNAs in the pathogenesis of melanoma[J].Exp Mol Pathol,2020,117: 104558. DOI:10.1016/j.yexmp.2020.104558.
[13]	Ma W, Chen X, Wu X, et al. Long noncoding RNA SPRY4-IT1 promotes proliferation and metastasis of hepatocellular carcinoma via mediating TNF signaling pathway[J].J Cell Physiol,2020,235(11): 7849-7862. DOI:10.1002/jcp.29438. pmid:31943198
[14]	Li Z, Shen J, Chan MTV, et al. The long non-coding RNA SPRY4-IT1: an emerging player in tumorigenesis and osteosarcoma[J].Cell Prolif,2018,51(4): e12446. DOI:10.1111/cpr.12446.
[15]	Xiang Y, Chen Y, Shi Y, et al. Upregulation of the long non-coding RNA SPRY4-IT1 predicts poor prognosis in breast cancer[J].Int J Clin Exp Pathol,2019,12(3): 1003-1008.
[16]	王焱, 仰大贵, 杨令芝. 乳腺癌组织SPRY4-IT1表达水平及其对患者远期生存的预测价值[J].华中科技大学学报(医学版),2019,48(1): 93-97. DOI:10.3870/j.issn.1672-0741.2019.01.018.
[17]	Mohebi M, Sattari A, Ghafouri-Fard S, et al. Expression profiling revealed up-regulation of three lncRNAs in breast cancer samples[J].Exp Mol Pathol,2020,117: 104544. DOI:10.1016/j.yexmp.2020.104544.
[18]	Zhang Y, Chen H, Yuan R, et al. PDK1-stabilized lncRNA SPRY4-IT1 promotes breast cancer progression via activating NF-κB signaling pathway[J].Mol Carcinog,2023,62(7): 1009-1024. DOI:10.1002/mc.23542.
[19]	Hassine S, Bonnet-Magnaval F, Benoit Bouvrette LP, et al. Staufen1 localizes to the mitotic spindle and controls the localization of RNA populations to the spindle[J].J Cell Sci,2020,133(14): jcs247155. DOI:10.1242/jcs.247155.
[20]	Zhao L, Jiang L, Zhang M, et al. NF-κB-activated SPRY4-IT1 promotes cancer cell metastasis by downregulating TCEB1 mRNA via Staufen1-mediated mRNA decay[J].Oncogene,2021,40(30): 4919-4929. DOI:10.1038/s41388-021-01900-8. pmid:34163032
[21]	Wang HF, Dong ZY, Yan L, et al. The N-terminal polypeptide derived from vMIP-Ⅱ exerts its antitumor activity in human breast cancer through CXCR4/miR-7-5p/Skp2 pathway[J].J Cell Physiol,2020,235(12): 9474-9486. DOI:10.1002/jcp.29755.
[22]	Yang QL, Zhang LY, Wang HF, et al. The N-terminal polypeptide derived from viral macrophage inflammatory protein Ⅱ reverses breast cancer epithelial-to-mesenchymal transition via a PDGFRα-dependent mechanism[J].Oncotarget,2017,8(23): 37448-37463. DOI:10.18632/oncotarget.16394.
[23]	Wu H, Wang Y, Chen T, et al. The N-terminal polypeptide derived from vMIP-Ⅱ exerts its anti-tumor activity in human breast cancer by regulating lncRNA SPRY4-IT1[J].Biosci Rep,2018,38(5): BSR20180411. DOI:10.1042/BSR20180411.
[24]	Shi Y, Li J, Liu Y, et al. The long noncoding RNA SPRY4-IT1 increases the proliferation of human breast cancer cells by upregulating ZNF703 expression[J].Mol Cancer,2015,14: 51. DOI:10.1186/s12943-015-0318-0. pmid:25742952
[25]	Zhang X, Mu X, Huang O, et al. ZNF703 promotes triple-negative breast cancer cells through cell-cycle signaling and associated with poor prognosis[J].BMC Cancer,2022,22(1): 226. DOI:10.1186/s12885-022-09286-w. pmid:35236318
[26]	Song X, Zhang X, Wang X, et al. LncRNA SPRY4-IT1 regulates breast cancer cell stemness through competitively binding miR-6882-3p with TCF7L2[J].J Cell Mol Med,2020,24(1): 772-784. DOI:10.1111/jcmm.14786. pmid:31736268
[27]	Zheng A, Zhang L, Song X, et al. Clinical significance of SPRY4-IT1 in efficacy and survival prediction in breast cancer patients undergoing neoadjuvant chemotherapy[J].Histol Histopathol,2020,35(4): 361-370. DOI:10.14670/HH-18-175. pmid:31638266
[28]	El-Helkan B, Emam M, Mohanad M, et al. Long non-coding RNAs as novel prognostic biomarkers for breast cancer in Egyptian women[J].Sci Rep,2022,12(1): 19498. DOI:10.1038/s41598-022-23938-8. pmid:36376369
[29]	Qin X, Yin Q, Gao J, et al. Prognostic role of SPRY4-IT1 in female breast carcinoma and malignant tumors of the reproductive system: a meta-analysis[J].Medicine (Baltimore),2022,101(16): e28969. DOI:10.1097/MD.0000000000028969.
[30]	Wang HM, Li HJ, Chen JZ, et al. Prognostic value of long nonco-ding RNA SPRY4-IT1 on survival outcomes in human carcinomas: a systematic review and meta-analysis with TCGA database[J].Biomed Res Int,2020,2020: 5868602. DOI:10.1155/2020/5868602.
[31]	Pourramezan Z, Attar FA, Yusefpour M, et al. Circulating lncRNAs landscape as potential biomarkers in breast cancer[J].Cancer Rep (Hoboken),2023,6(2): e1722. DOI:10.1002/cnr2.1722.
[32]	Wasson MD, Brown JM, Venkatesh J, et al. Datasets exploring putative lncRNA-miRNA-mRNA axes in breast cancer cell lines[J].Data Brief,2021,37: 107241. DOI:10.1016/j.dib.2021.107241.

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References32

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234.
[3]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.
[4]	Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82.
[5]	Gu Huayan, Zhu Teng, Guo Guilong.Breast microbiota and breast cancer： present and future[J]. Journal of International Oncology, 2024, 51(1): 55-58.
[6]	Wang Jing, Xu Wenting.Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm[J]. Journal of International Oncology, 2023, 50(9): 520-526.
[7]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying.Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients[J]. Journal of International Oncology, 2023, 50(9): 527-531.
[8]	Liu Yang, Jiang Lulu, Guan Kaiwen, Zhou Yueyang, Kang Xiaohong.Role of linc01410 in the occurrence and development of malignant tumors[J]. Journal of International Oncology, 2023, 50(9): 540-543.
[9]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng.Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway[J]. Journal of International Oncology, 2023, 50(8): 449-456.
[10]	Pan Shulan, Liu Chang, He Ping.Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer[J]. Journal of International Oncology, 2023, 50(8): 457-462.
[11]	Wang Wende, Zeng De.Research progress on the mechanism of endocrine therapy resistance for breast cancer[J]. Journal of International Oncology, 2023, 50(6): 352-356.
[12]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367.
[13]	Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin.lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway[J]. Journal of International Oncology, 2023, 50(4): 202-207.
[14]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong.Research progress on targeted therapy of breast cancer with low expression of HER2[J]. Journal of International Oncology, 2023, 50(4): 236-240.
[15]	Zhou Ting, Xu Shaohua, Mei Lin.Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer[J]. Journal of International Oncology, 2023, 50(3): 144-149.